European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic : part 1-epidemiology, pathophysiology, and diagnosis
This article has been co-published with permission in the European Heart Journal and Cardiovascular Research. © The European Society of Cardiology 2021. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article..
AIMS: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19.
METHODS AND RESULTS: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19.
CONCLUSION: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Cardiovascular research - 118(2022), 6 vom: 06. Mai, Seite 1385-1412 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
ACE2 |
|---|
| Anmerkungen: |
Date Completed 10.05.2022 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cvr/cvab342 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33401624X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33401624X | ||
| 003 | DE-627 | ||
| 005 | 20240320232647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvab342 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM33401624X | ||
| 035 | |a (NLM)34864874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Task Force for the management of COVID-19 of the European Society of Cardiology |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic |b part 1-epidemiology, pathophysiology, and diagnosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2022 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This article has been co-published with permission in the European Heart Journal and Cardiovascular Research. © The European Society of Cardiology 2021. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. | ||
| 520 | |a AIMS: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19 | ||
| 520 | |a METHODS AND RESULTS: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19 | ||
| 520 | |a CONCLUSION: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a Arrhythmias | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiogenic shock | |
| 650 | 4 | |a Myocardial injury | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Non-invasive imaging | |
| 700 | 1 | |a Baigent, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Windecker, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Andreini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Arbelo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Barbato, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Bartorelli, Antonio L |e verfasserin |4 aut | |
| 700 | 1 | |a Baumbach, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Behr, Elijah R |e verfasserin |4 aut | |
| 700 | 1 | |a Berti, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno, Héctor |e verfasserin |4 aut | |
| 700 | 1 | |a Capodanno, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Cappato, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Chieffo, Alaide |e verfasserin |4 aut | |
| 700 | 1 | |a Collet, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Cuisset, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a de Simone, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Dendale, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Dudek, Dariusz |e verfasserin |4 aut | |
| 700 | 1 | |a Edvardsen, Thor |e verfasserin |4 aut | |
| 700 | 1 | |a Elvan, Arif |e verfasserin |4 aut | |
| 700 | 1 | |a González-Juanatey, José R |e verfasserin |4 aut | |
| 700 | 1 | |a Gori, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Grobbee, Diederick |e verfasserin |4 aut | |
| 700 | 1 | |a Guzik, Tomasz J |e verfasserin |4 aut | |
| 700 | 1 | |a Halvorsen, Sigrun |e verfasserin |4 aut | |
| 700 | 1 | |a Haude, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Heidbuchel, Hein |e verfasserin |4 aut | |
| 700 | 1 | |a Hindricks, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Ibanez, Borja |e verfasserin |4 aut | |
| 700 | 1 | |a Karam, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Katus, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Klok, Fredrikus A |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinides, Stavros V |e verfasserin |4 aut | |
| 700 | 1 | |a Landmesser, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Leclercq, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Leonardi, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Lettino, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Marenzi, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Mauri, Josepa |e verfasserin |4 aut | |
| 700 | 1 | |a Metra, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Morici, Nuccia |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Petronio, Anna Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Polovina, Marija M |e verfasserin |4 aut | |
| 700 | 1 | |a Potpara, Tatjana |e verfasserin |4 aut | |
| 700 | 1 | |a Praz, Fabien |e verfasserin |4 aut | |
| 700 | 1 | |a Prendergast, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Prescott, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Pruszczyk, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Leor, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Roffi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Romaguera, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenkranz, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkozy, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Scherrenberg, Martijn |e verfasserin |4 aut | |
| 700 | 1 | |a Seferovic, Petar |e verfasserin |4 aut | |
| 700 | 1 | |a Senni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Spera, Francesco R |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanini, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Thiele, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasoni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Torracca, Luccia |e verfasserin |4 aut | |
| 700 | 1 | |a Touyz, Rhian M |e verfasserin |4 aut | |
| 700 | 1 | |a Wilde, Arthur A |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Bryan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g 118(2022), 6 vom: 06. Mai, Seite 1385-1412 |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2022 |g number:6 |g day:06 |g month:05 |g pages:1385-1412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvab342 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2022 |e 6 |b 06 |c 05 |h 1385-1412 | ||